RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Kimchi power for Irritable Bowel Syndrome - Diarrhoea

The investigators will conduct a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to investigate the effects of Kimchi powder supplementation on gut health in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) for 8 weeks.

Official registry: https://clinicaltrials.gov/study/NCT07749092 · Pusan National University Yangsan Hospital · enrollment listed as 100

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Kimchi power, or Placebo. The registry lists allocation as randomized. The investigators will conduct a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to investigate the effects of Kimchi powder supplementation on gut health in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) for 8 weeks.

They plan to enroll about 100 people at Yangsan. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

The Effect of Kimchi Powder Supplementation on Gut Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (KIMCHI-GUT Trial)

Interventions: Kimchi power, Placebo

Primary outcome (registry wording): Change in IBS Severity Scoring System (IBS-SSS) total score

Who it is for (from inclusion criteria)

Ages 20 Years to 70 Years
Adults, male or female, aged 20 to 70 years
Body mass index of 25 kg/m2 or more and less than 30 kg/m2
Meeting the Rome IV criteria for diarrhea-predominant irritable bowel syndrome (IBS-D), defined as Bristol Stool Form Scale type 6 or 7 in 25% or more of bowel movements from 2 weeks before screening through the day of the screening visit
No inflammatory bowel disease or malignancy
Provided written agreement to refrain from consuming kimchi-containing foods for the duration of the study (approximately 2 months)

Who the registry excludes

Drug-induced constipation
Constipation secondary to another condition, such as diabetes mellitus or thyroid disease
History of intra-abdominal surgery other than appendectomy (including gastrectomy, gastric bypass, gallbladder or biliary tract surgery, pancreatectomy, bowel resection with particular reference to the ileum, and colorectal surgery or insertion procedures)
Uncontrolled hypertension (resting blood pressure 160/100 mmHg or higher)
Uncontrolled diabetes mellitus (fasting blood glucose 160 mg/dL or higher)
Uncontrolled hypothyroidism or hyperthyroidism
AST or ALT concentration 3 times or more the upper limit of the reference range of the testing laboratory

Public study contact (from the registry)

Professor

+82-55-360-2860

drsaylee@gmail.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Pusan National University Yangsan Hospital — Yangsan, South Korea (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseLeuven, Vlaams-Brabant

Not a traditional drug phase: Sample collection for IBS

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

NCT02421705 · Official ClinicalTrials.gov record · KU Leuven

RecruitingNot a traditional drug phaseRochester, Minnesota

Mucosal and Microbiota Changes During Acute Campylobacteriosis

Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS).

NCT03223077 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingPhase 2 / Phase 3Ann Arbor, Michigan

Phase 2 / Phase 3: testing Lexapro for Irritable Bowel Syndrome With Constipation

This study will assess the how well it works of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.

NCT05519683 · Official ClinicalTrials.gov record · University of Michigan

FAQ about this NCT record

Is NCT07749092 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07749092?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07749092?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary